NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









a:head bio AG

a:head bio AG

Private
ViennaHealthcare & Life Scienceshttps://aheadbio.com/

Last Round

Early Funding

Apr 17, 2025

Total Funding Raised

$7.23M

Company Overview

a:head bio AG is a biotechnology company that develops novel therapeutics for the treatment of central nervous system disorders using a proprietary human cerebral organoid drug discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

cerebral organoidsCNS drug discoveryorganoid-on-a-chipdisease modeling3D tissue cultureneurological therapeuticsdrug screeninganimal model replacementin vitro modelsAI-driven drug discoveryorganoid technologybiotech R&D servicesneurodegenerative researchnew approach methodologiesNAMs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

a:head bio AG Comparables

Compare a:head bio AG with similar companies based on industry and business-model similarity.

a:head bio AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Herophilus
90%
28bio
87%
Synaxys
86%

a:head bio AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 17, 2025
VC RoundOct 9, 2024
GrantOct 25, 2019
SeedAug 7, 2019

Key People

Founding team and executive leadership

Oliver Szolar

CEO

Executive Team

a:head bio AG Investors

Notable investors and investment history

a:head bio AG investors
InvestorRounds
FFG Austrian Research Promotion AgencyGrant
red-stars.com dataSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 3, 2026

    Grew 54% QoQ, from 13 to 20 employees.

a:head bio AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

a:head bio AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about a:head bio AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersVienna
Employee Range20
Year Founded2019
Last FundingApr 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.